Health Affairs December 1, 2024
Rena M. Conti, Claire Mcglave, Meredith B. Rosenthal, Danielle Rodin

Abstract

Prices of anticancer medicines (including chemically synthesized medicines and biologics manufactured from living organisms) are a subject of concern, as they contribute to spending by health plans and patients. We describe prices and evaluate the impact of competition among 185 anticancer medicines, using IQVIA data from the period October 2014–February 2020. We calculated the price of each medicine, defined as volume-weighted wholesale costs net of prompt-pay discounts and gross of rebates, without and with inflation adjustment, and summarized them by patent status, formulation, and therapeutic class. We evaluated the relationship between prices and competition, using regression analyses. We also conducted...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
STAT+: Nobel laureates call on National Academies and biotech CEOs to speak out against Trump attacks on science
New Data Shed Light on Who Stops Using GLP-1 Drugs, and Why
STAT+: DeepSeek signals China’s rising influence in AI — and AI drug development
FDA Approves Third Tocilizumab Biosimilar
India targets to sequence 10 million genomes

Share This Article